A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
$650m buys the group rights to RemeGen’s RC148.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
After Aktis's $318m flotation Eikon is a bigger proposition.
Readout of the Pivot-006 trial is brought forward by nearly a year.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
